IPO Report: Recro Pharma (REPH)

Francis Gaskins  |

Recro Pharma (REPH) is a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain based in Malvern, PA,.

Three other IPOs are scheduled for the week of March 3, 2014. The entire IPO calendar is available at IPOpremium.

The manager is  joint managers: Aegis Capital

The co-managers is Brean Capital.
SEC Filings

REPH is a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting.




Valuation Ratios


Price /

Price /

Price /

Price /

% offered

Trade Commission-FREE with Tradier Brokerage


Cap (mm)





in IPO

Recro Pharma (REPH)















REPH has no collaboration partners, shareholders aren’t indicating buying on the IPO, intellectual property is from licenses rather than internal development and the lead candidate has only completed Phase 1b clinical trials (very early stage).

The rating on REPH is avoid.

REPH is a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting.

REPH has studied various dosage forms of Dex in eight completed clinical trials, including two placebo controlled trials that demonstrated effective pain relief.

Dex, which is in a class of drugs called alpha-2 adrenergic agonists, is an FDA approved and commercial injectable drug sold by Hospira in the United States under the brand name Precedex® and by Orion in Europe under the brand name Dexdor®.

As Dex is not an opioid based drug, REPH expects to overcome many of the side effects associated with commonly prescribed opioid based therapeutics, including addiction, constipation and respiratory distress while maintaining analgesic, or pain relieving, effect.

If REPH is successful in obtaining approval of Dex-IN, its proprietary intranasal formulation of Dex, for post-operative pain, REPH may elect to pursue additional approvals for cancer breakthrough pain and/or non-cancer breakthrough pain.

Upon regulatory approval, REPH’s license with Orion and its ownership rights with respect to dosage forms for its product candidates will provide REPH worldwide commercial rights related to Dex, except in Europe, Turkey and the CIS for use in the treatment of pain in humans in multiple dosage forms.

REPH is a development stage company with a limited operating history.

It has funded its operations to date primarily from the private placement of convertible preferred stock and proceeds received from its convertible notes private placements.

From inception through December 31, 2013, REPH has received net proceeds of $4 million from the sale of convertible preferred stock and $9.4 million from the sale of its convertible notes in private placements.


The pharmaceutical and biotechnology industries are intensely competitive and subject to rapid and significant technological change. REPH current and future competitors include pharmaceutical, biotechnology and specialty pharmaceutical companies.

Many of REPH’s  competitors have greater financial and other resources than REPH has, such as more commercial resources, larger research and development staffs and more extensive marketing and manufacturing organizations. As a result, these companies may obtain marketing approval more rapidly than REPH is able and may be more effective in selling and marketing their products. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies.

REPH’s competitors may succeed in developing, acquiring or licensing technologies and drug products that are more effective or less costly than its product candidates or any other products that REPH may develop which could render its products obsolete and noncompetitive.

REPH expects any products that it develops and commercializes to compete on the basis of, among other things, efficacy, safety, convenience of administration and delivery, price and the availability of reimbursement from government and other third-party payers. REPH also expects to face competition in its efforts to identify appropriate collaborators or partners to help commercialize its product candidates in our target commercial markets.

In cancer breakthrough pain relief, REPH expects to compete against established companies, including Teva Pharmaceutical Industries, Ltd., Meda AB, Kyowa Hakko, Insys Therapeutics, Inc. and Archimedes Pharma Ltd.

All of these potential competitors have various formulations of fentanyl, a fast-acting opioid. REPH is not aware of any non-fentanyl related therapeutics in development for the treatment of cancer breakthrough pain.

5% stockholders

SCPVitalife Partners II, L.P.  58.8%

SCPVitalife Partners (Israel) II, L.P. 19.7%

Churchill Trust    5.2%

Thomas F. Henwood 15.9%      

Use of proceeds

REPH expects to net $24.5 million from its IPO. Proceeds are allocated as follows:

$2.1 million for its planned Dex-IN post-operative pain Phase IIb trial following orthopedic surgery, specifically bunionectomy surgery;

$8 million for two Dex-IN post-operative pain Phase III pivotal trials, one following intra-abdominal surgery and one following orthopedic surgery;

$1.5 million for preclinical animal toxicology studies;

$5 million for human safety clinical trials and manufacturing work for Dex-IN, including the preparation of registration and stability batches and packaging of clinical materials; and

the remainder to fund working capital needs and other general corporate purposes.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not necessarily represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.

Market Movers

Sponsored Financial Content